All In Biotech

Drug Trial Radar · NCT03614234

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Adult Patients With Fabry Disease

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

29

Actual

Start

Nov 13, 2018

Primary completion

Apr 13, 2026

Study completion Apr 13, 2026

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Aug 3, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of CLI-06657AA1-03 (formerly PB-102-F51) is to evaluate the long-term safety, tolerability, and efficacy of 2 mg/kg pegunigalsidase alfa administered intravenously every four weeks in adult Fabry patients who have successfully completed PB-102-F50.

Conditions

  • Fabry Disease

Interventions

  • pegunigalsidase alfaDrug

    Recombinant human alpha galactosidase A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of treatment-related adverse eventsTime frame: Throughout the study, 364 weeks

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • UAB Medicine

    Birmingham, Alabama

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Iowa Hospitals and Clinica

    Iowa City, Iowa

  • Infusion Associates

    Grand Rapids, Michigan

  • Renal Disease Research Institute, LLC

    Dallas, Texas

  • University of Utah Hospitals & Clinics

    Salt Lake City, Utah

  • O & O Alpan

    Fairfax, Virginia

  • UZ Antwerpen

    Edegem, Belgium

  • Fakultní poliklinika Všeobecné fakultní nemocnice v Praze

    Prague, Czechia

  • Medical Endocrinology PE 2132, Rigshospitalet

    Copenhagen, Denmark

  • Azienda Ospedaliera Universitaria "Federico II"

    Naples, Via Pansini, Italy

  • Helse Bergen HF Haukeland Universitetssykehus

    Bergen, Norway

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • The Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.